All In Biotech

Drug Trial Radar · NCT06501443

LATAM LOWERS LDL-C

Latin America Lipid Optimization After Acute Event in Patients With AthErosclerotic CardiovasculaR DiseaSe and High LDL-C

Last checked: Nov 20, 2026Latest source record: Dec 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 520 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

520

Planned (sponsor's estimate)

Start

Feb 11, 2025

Primary completion

Nov 27, 2026

Study completion Nov 29, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, patient-level 1:1 randomized clinical trial in a multi-country study aiming to evaluate the real-world impact of inclisiran + Usual Care (UC) vs UC alone on LDL-C lowering, patient-reported outcomes, and healthcare resource utilization in an in-hospital population of patients, admitted during the acute setting, stabilized and before discharge, following an acute cardiovascular event.

Conditions

  • Hypercholesterolaemia

Interventions

  • Usual careDrug

    Treatment after acute event approved in the country where patient is based. It may include educational intervention according to each country guidelines

  • KJX839Drug

    Inclisiran in solution for subcutaneous injection on day 1, day 90, and day 270

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in LDL-C from baseline to 330 daysTime frame: Baseline and Day 330

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Corrientes, Argentina · Recruiting

  • Novartis Investigative Site

    Campina Gde Do Sul, Brazil · Recruiting

  • Novartis Investigative Site

    Salvador, Brazil · Recruiting

  • Novartis Investigative Site

    Salvador, Estado de Bahia, Brazil · Recruiting

  • Novartis Investigative Site

    Belo Horizonte, Minas Gerais, Brazil · Recruiting

  • Novartis Investigative Site

    Belo Horizonte, Minas Gerais, Brazil · Recruiting

  • Novartis Investigative Site

    Campo Largo, Paraná, Brazil · Recruiting

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Novartis Investigative Site

    Blumenau, Santa Catarina, Brazil · Withdrawn

  • Novartis Investigative Site

    São José, Santa Catarina, Brazil · Recruiting

  • Novartis Investigative Site

    São José, São Paulo, Brazil · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.